In­smed’s PhII smokes and sput­ters, but re­searchers her­ald enough sur­pris­ing­ly pos­i­tive da­ta to roar on Wall Street

There was plen­ty not to like in In­smed’s Phase II read­out of an an­ti-in­flam­ma­to­ry drug dubbed INS1007.

The dose re­sponse didn’t pan out and in fact, the high dose missed on a key end­point that could be the piv­otal goal need­ed for an ap­proval. But with sev­er­al an­a­lysts ex­pect­ing the whole thing to be a bust, in­vestors cheered on ev­i­dence of pos­i­tive ef­fi­ca­cy in treat­ing non-cys­tic fi­bro­sis bronchiec­ta­sis and ran up the stock price $IN­SM by 40%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER